2002 - Paris - France

2002 - Paris - France

Thursday June 6
08:00-08:45 Registration and coffee
08:45-09:00 Welcome and Introduction
Oral session I Drug - Drug Interactions chair: Janet Wade
09:00-09:20 Andreas Freidig Development Of A PBPK Model For Drug-Drug Interaction Of Orally Delivered Drugs Using In-Vitro Data
09:20-09:40 Christian Laveille Simulations Using A Mechanistic DDI Model : Individual Risk Assessment
09:40-10:00 Marie Gårdmark EU Regulatory View On DDI And Population Analyses
10:00-11:00 Coffee break, Poster and Software session I
Posters in Group I are accompanied by their presenter (see below)
Oral session II chair: Leon Aarons
11:00-11:30 Jan Freijer Extrapolation Of Pharmacokinetics And Toxicity From Pre-Clinical Data To Humans
11:30-11:50 Elena Mishina Assessment Of The Contribution Of Components In A Combination Drug Product Using Population PK Modeling
11:50-12:10 Iñaki F. Trocóniz Dealing With Autoinhibition Of Drug Clearance In Early Clinical Product Development
12:10-12:30 Vladimir Piotrovsky Drug Efficacy Analysis As An Exercise In Dynamic (Indirect-Response) Population PK-PD Modeling
12:30-14:00 Lunch
Oral session III Data transformation, Parameter transformation chair: Lewis Sheiner
14:00-14:40 Jose Pinheiro Transformations and Variance Functions in Nonlinear Mixed-Effects Models
14:40-15:00 Pascal Girard

Data transformation and Parameter Transformations in NONMEM (PDF of Presentation)

15:00-16:00 Tea, Posters and Software
Oral session IV PK/PD chair: Oscar Della Pasqua
16:00-16:20 Robert Leary A Unified Parametric/Nonparametric Approach To PK/PD Population Modeling
16:20-16:40 Celine Brochot Assessing The Additivity Of The Effects Of Drugs In Mixtures
16:40-17:00 Nick Holford Population Disease Progress Models For The Time Course Of HAMD Score In Depressed Patients Receiving Placebo In Anti-Depressant
17:00-17:30 Planning of future PAGE meetings & organization
For all those interested
19:00-24:00 Social Evening

Friday June 7
Oral session V chair: Pascal Girard
09:00-09:20 Stefano Zamuner Estimate The Time Varying Brain Receptor Occupancy In PET Imaging
09:20-09:40 Michael Looby Assessing The Robustness Of Competing Dose Regimens To Incomplete Compliance
09:40-10:00 Eric Snoeck Model Evaluation
10:00-11:00 Coffee, Poster and Software session II
Posters in Group II are accompanied by their presenter (see below)
Tutorial chair: Ferdie Rombout
11:00-11:30 Charles Warlow Sub-group Nonsense. Problems In Interpreting And Considering Covariates In Evaluation
Oral session VI Special Populations chair: Eric Snoeck
11:30-11:50 Bruce Green Population Pharmacokinetics And Pharmacodynamics Of Enoxaparin In Obese Patients
11:50-12:10 Oscar Della Pasqua/Eliane Fuseau Optimising Design in Pediatric Regulatory Studies
12:10-12:30 Brigitte Tranchand/Silvy Laporte Design And Practical Problems In Population PK Studies In The Elderly
12:30-14:00 Lunch
Oral session VII Study Design chair: France Mentré
14:00-14:20 Stephen Duffull Prospective Assessment Of A D-Optimal Design For A Population Pharmacokinetic Study Of Enoxaparin
14:20-14:40 Sylvie Retout Optimisation Of Individual And Population Pharmacokinetic Designs Using S-Plus
14:40-15:00 Billy Amzal Bayesian Optimal Design For The Study Of Butadiene Toxicokinetics
15:00-16:00 Tea, Posters and Software
Oral session VIII chair: Janet Wade
16:00-16:40 Lewis Sheiner Dealing with Missing Data Through Random Effects Models
16:40-17:00 Concluding remarks/preview PAGE 2003, Verona

Posters Thursday (group I)

Michel Tod Handling Concentrations Below Quantification Limit In Population
Sandrine Micallef Modelling Of Intra-Individual And Inter-Individual Variability In 1,3-Butadiene Metabolism
Liping Zhang Simultaneous Vs. Sequential Estimation In PK/PD Data Analysis
Sophie Gisbert Incorporating Uncertainty And Variability In The Physiological Parameters Of A PBPK Model
Ivelina Gueorguieva Reducing PBPK Models Using Global Sensitivity Analysis And Benefit/Cost Criterion
Chanu Pascal Population Pharmacokinetics Of Epirubicin And Its Main Metabolite Epirubicinol Using NONMEM
Sylvie Saivin Cefepime Monitoring In ICU Patients Using A Population Pharmacokinetic Approach
Kim Emil Andersen A Bayesian Approach To Bergman's Minimal Model
Ulrika Wählby Handling Of Time-Varying Covariates In Population Model Building
Susanne Bøttcher Bayesian Networks Used In PK/PD Modelling
Sylvie Saivin Validation Of An Amikacin Population Pharmacokinetics Model To Be Used In Intensive Care Unit
René Bruno Assessment Of The Predictive Performance Of A New Population Pharmacokinetic Model For Trastuzumab (Herceptin) And Simulation Of Trastuzumab Steady-State Exposure During Long-Term Weekly Dosing
Andreas Groth Discussion Of Criteria For Evaluating The Quality Of Glucose Clamp Studies
María José García Sánchez Population Pharmacokinetics Of Long-Term Methotrexate In Children With Lymphoblastic Leukemia
María José García Sánchez Phenytoin Covariate Models For Michaelis-Menten Pharmacokinetics In Adult Epileptic Patients
Chantal Csajka Population Pharmacokinetics And Effects Of Efavirenz In Hiv Patients
Jakob Ribbing The Effect Of Collinearity On The Selection Of Covariates In Population Pharmacokinetic Analysis
Hussain Mulla Population Pharmacokinetics Of Theophylline During Paediatric Extracorporeal Membrane Oxygenation (ECMO)
Marta Valle Pharmacokinetics Of The Three Main Alkaloids Present In The South American Psychoactive Beverage Ayahuasca After Oral Administration To Healthy Volunteers
Siv Jonsson Estimating Bias In Parameters For Some NONMEM Models For Ordered Categorical Data

Posters Friday (group II)

Juan Jose Perez Ruixo Population Pharmacokinetic Analysis Of Zarnestra Using Data From Phase I Clinical Trials
Jean-Baptiste Fau Population PK/PD Modelling Of A New Mao-B Inhibitor In Young And Elderly Healthy Volunteers
Valerie Cosson Efficiency Of Using Population Pharmacokinetics To Demonstrate Bioequivalence With Sparse Sampling In Cancer Patients- A Trial Simulation With Etoposide
An Vermeulen Modelling Of The Effect Of Carbamazepine On The Pharmacokinetics Of Risperidone In Psychotic Patients Of Different Phenotypes
Yann Merle Nonparametric Population Analysis Of Amikacin Pharmacokinetic Data In A Pediatric Population
Laurent Claret The Use Of A Stochastic Model For Data Exhibiting Heterogeneous Pharmacokinetics
Laurent Nguyen Population Pharmacokinetics Of Vinflunine From Phase I Data And Evaluation Of Population Sampling Designs For Further Clinical Development
Xuejun Chen Population PK Modeling Of Drugs Exhibiting Less Than Proportional Increases In Pharmacokinetics Relative To Increasing Doses
Amy Yao Population Pharmacokinetics Of Cyclophosphamide And Its Metabolites In Hematopoietic Stem-Cell Transplantation Patients
Athanassios Iliadis Information Indexes For Exploratory Data Analysis In Population Pharmacokinetics
Sophie Glatt Pooled PK Analysis Of Interferon-Beta-1a (Rebif), Data Obtained In Healthy Subjects And In Patients
Lars Lindbom Symmetry And Coverage Of Confidence Intervals For A Population PK Model
Ziad Hussein Retrospective Population Pharmacokinetics Of Cetirizine In Infants And Children
Xiaofeng Wang Population Pharmacokinetics Model Validation Using Kinetica
Nathalie Perdaems The Use Of Physiologically Based Pharmacokinetic (PBPK) Model In Drug Development
Laurence Del Frari Pharmacokinetic Mixed Effects Modelling Of S 16257 After Oral Administration In The Beagle Dog; Combined Analysis
Annabelle Diot Gauss Hermite Quadrature In Population Parameters Estimation. Application To The Detection Of Subpopulations
Hui Kimko Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
Florence Hourcade-Potelleret Mixture models : simulation and estimation with NONMEM
Judith L. Jacobsen Grey-box Modelling of Insulin Clamp Study
Delphine Martin Pharmacokinetic mixed effects modelling of a new compound in rat - Combined analysis
In-Sun Nam The propagation of information in PK modelling: The use of IV information to support the analysis of PK data
Gudrun Wuerthwein Population Pharmacokinetics of High-Dose Etoposide in Children Receiving Different Conditioning Regimens